Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy.
Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy.
复制标题
可溶性细胞毒性 T 淋巴细胞抗原 4：治疗后恶性肿瘤的良好预测因子
DOI：
10.2147/ott.s128451
复制
发表时间：
2017
影响因子：
4
通讯作者：
Zhang J
中科院分区：
文献类型：
--
作者：
Liu Q;Hu P;Deng G;Zhang J;Liang N;Xie J;Qiao L;Luo H;Zhang J
特此接受条款。未经Dove Medical Press Limited的进一步许可，允许将本作品用于非商业用途，前提是本作品具有适当的归属。有关本工作的商业使用许可，请参见我们的条款第4.2和5段目的：可溶性细胞毒性T淋巴细胞抗原4（sCTLA-4），CTLA-4的亚型之一，被发现在下调T细胞应答中CTLA-4的负信号中至关重要。与CTLA-4的经典免疫抑制作用相反，其免疫调节功能可能是复杂的。然而，sCTLA-4对免疫调节的临床意义以及在癌症治疗中的变化尚未阐明。我们推测sCTLA-4水平可能影响癌症预后。患者和方法：测定141例局部晚期和晚期癌症患者治疗前后血清sCTLA-4浓度，并进行生存分析。计算总生存期（OS）的风险比和95%置信区间。通过整个患者sCTLA-4水平的中位数确定临界值。结果：治疗后sCTLA-4高表达者OS和PFS明显延长（P均0.01）。各亚组治疗后sCTLA-4水平均较治疗前1 d显著升高，且与肿瘤淋巴结转移分期、淋巴结转移呈负相关（均P0. 05）。多因素分析显示sCTLA-4水平是影响OS和PFS的独立预后因素（均P < 0. 05）。结论：我们的数据证明了sCTLA-4的良好预后意义，并可能导致癌症患者新的免疫治疗选择的发展。
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms Purpose: Soluble cytotoxic T-lymphocyte antigen 4 (sCTLA-4), one of the isoforms of CTLA-4, was discovered to be critical in downregulating the negative signal of CTLA-4 in T-cell responses. Contrary to the classical immunosuppressive effect of CTLA-4, its immuno-regulatory function might be complicated. However, the clinical significance of sCTLA-4 to immune regulation and the variation in cancer therapy have not been elucidated. We postulated that the level of sCTLA-4 might affect the outcome of cancer prognosis. Patients and methods: Serum concentrations of sCTLA-4 before and after therapy in 141 locally advanced and advanced cancer patients were measured and survival analyses was performed. Hazard ratio and 95% confidence interval for overall survival (OS) were calculated. Cutoffs were determined by median across the sCTLA-4 level of entire patients. Results: High expression of sCTLA-4 after therapy indicated significant longer OS and progression-free survival (PFS) (all P,0.01). Among all subgroups, sCTLA-4 levels after therapies were found to be significantly higher than that of 1 day before, which was also negatively correlated with tumor node metastasis stage and lymph node metastasis (all P,0.05). Multivariate analysis revealed that sCTLA-4 level was a strong independent prognostic factor for OS and PFS (all P,0.05). Conclusion: Our data demonstrated the favorable prognostic significance of sCTLA-4 and may lead to the development of new immunotherapy options for cancer patients.